Mostaghel, Elahe A.

Integrative Clinical Genomics of Advanced Prostate Cancer

Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 3,645

Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth

Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research

Prostate Cancer Treatment and ResearchCancer, Lipids, and Metabolism

Cited by 1,419

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 748

Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling

Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., et al. (2017) · Cancer Cell

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 744

Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist after Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate Cancer

Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research

Prostate Cancer Treatment and ResearchHormonal and reproductive studies

Cited by 529

Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism: A Randomized Controlled Trial

Marks, L. S., Mazer, N. A., Mostaghel, E., Hess, D. L., Dorey, F. J., Epstein, J. I., Veltri, R. W., Makarov, D. V., Partin, A. W., Bostwick, D. G., et al. (2006) · JAMA

Hormonal and reproductive studiesProstate Cancer Treatment and Research

Cited by 400

Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men

Page, S. T., Lin, D. W., Mostaghel, E. A., Hess, D. L., True, L. D., Amory, J. K., Nelson, P. S., Matsumoto, A. M., & Bremner, W. J. (2006) · The Journal of Clinical Endocrinology & Metabolism

Prostate Cancer Treatment and ResearchHormonal and reproductive studies

Cited by 229

SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

Yang, M., Xie, W., Mostaghel, E., Nakabayashi, M., Werner, L., Sun, T., Pomerantz, M., Freedman, M., Ross, R., Regan, M., et al. (2011) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPharmacogenetics and Drug Metabolism

Cited by 159

11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): implications for castration resistant prostate cancer

Barnard, M., Quanson, J. L., Mostaghel, E., Pretorius, E., Snoep, J. L., & Storbeck, K.-H. (2018) · The Journal of Steroid Biochemistry and Molecular Biology

Prostate Cancer Treatment and ResearchAldose Reductase and Taurine

Cited by 72

Contribution of mouse adrenal glands to intratumor androgens and growth of castration-resistant prostate cancer xenografts

Mostaghel, E. A., Biehl, H., Hernandez, S., Zhang, A., Bartlett, J., Corey, E., Penning, T. M., Oksala, R., True, L. D., & Nelson, P. (2017) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchAdrenal Hormones and Disorders

Cited by 1